<?xml version="1.0" encoding="UTF-8"?>
<p>This document provides the perspective as of April 2020 of the Working Party on Global Blood Safety of the International Society of Blood Transfusion on use of COVID‐19 convalescent plasma as an experimental treatment for COVID‐19. The document addresses the following important factors to have in mind when considering this treatment: (A) eligibility criteria of convalescent COVID‐19 patients to donate whole blood or plasma; (B) pre‐screening and pre‐donation testing of convalescent COVID‐19 donors; (C) criteria for collection of COVID‐19 plasma; (D) post‐donation treatment of plasma; and (E) recommendations for plasma transfusion.</p>
